경희대학교병원

의료진 소개

종양혈액내과
윤성수 교수

관심의료진

초진

2026.04.08 13:30

재진

2026.04.08 13:30

전문분야

림프종, 다발성골수종, 양성혈액질환, 신약개발 임상시험

진료일정

진료과 센터 암병원

오전
오후

진료예약

직위

병원	교수

학력

1992 ~ 1996	서울대학교 대학원 내과학 박사
1985 ~ 1987	서울대학교 대학원 내과학 석사
1978 ~ 1984	서울대학교 의학과 학사

경력 및 연수

2014 ~ 2025	서울대학교 의과대학 협동과정 종양생물학전공 겸무 교수
2014 ~ 2025	서울대학교 의과대학 교수
2011 ~ 2020	서울대학교병원 암진료부문 진료부 혈액암센터장
2010 ~ 2014	서울대학교병원 진료부문 혈액종양내과 분과장
2010 ~ 2018	서울대학교병원 교육연구부장
2010 ~ 2010	서울대학교병원 진료부문 국제진료센터장
2008 ~ 2010	서울대학교병원 진료부문 진료협력담당 교수
2006 ~ 2007	서울대학교병원 교육연구부 전공의·수련담당 교수
2006 ~ 2013	서울대학교 의과대학 (기금)교수
2001 ~ 2006	서울대학교 의과대학 (기금)부교수
1997 ~ 2001	성균관대학교 의과대학 조교수
1995 ~ 1996	미국 Fred Hutchinson Cancer Research Center Clinical Fellow
1994 ~ 1997	삼성서울병원 내과 혈액종양분과 전문의
1992 ~ 1994	미국 Texas MD Anderson Cancer Center 연구원 (지도 교수: Prof. Isaiah Josh Fidler)
1992 ~ 1992	서울대학교 의과대학 암연구소 연구원
1991 ~ 1992	서울대학교병원 내과 혈액종양내과 전임의
1988 ~ 1991	내과 군의관
1985 ~ 1988	서울대학교병원 내과전공의
1984 ~ 1985	서울대학교병원 수련의

학회활동

~	대한암학회
~	대한내과학회
~	대한혈액학회
~	대한수혈학회
~	대한조혈모세포이식학회
~	대한종양내과학회
~	한국혈전지혈학회
~	한국유전체학회
~	ASCO (American Society of Clinical Oncology)
~	AACR (American Association of Cancer Research)
~	ASH (American Society of Hematology)
~	EHA (European Hematology Association)
~	ISEH (International Society of Experimental Hematology)
~	ICGC (International Cancer Genome Consortium): Executive board member/ Project leader

수상이력

2021	대한수혈학회 적십자 공로상 (2021년 5월 21일 학술대회에서 시상)
2019	대한혈액학회 학술상
2017	제21회 함춘의학상

논문

2025.07	Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study.
2025.07	Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia.
2025.03	Clonal hematopoiesis: elements associated with clonal expansion and diseases.
2025.01	Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication.
2024.12	Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.
2024.01	A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea.
2024.07	Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma.
2024.09	Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm.
2023.04	Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).
2023.10	Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma.
2022.11	Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
2023.03	Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation.
2023.12	Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes.
2022.09	Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment.
2022.01	Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM.
2022.02	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea.
2022.12	Expansion of Human Megakaryocyte-Lineage Progeny via Aryl Hydrocarbon Receptor Antagonism with CH223191.
2020.11	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
2021.11	Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations.
2025.07	Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.
2025.06	Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.
2025.06	Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based study.
2025.06	A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).
2025.07	Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide conditioning in patients with central nervous system lymphoma: a phase II study.
2025.05	Prognostic Landscape of TP53 Mutations in Hematologic Malignancies.
2025.05	Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies.
2025.05	Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry.
2025.04	Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma.
2025.05	Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
2025.08	Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.
2025.04	Comprehensive clinico-genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm.
2025.02	Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.
2025.01	Automated vs manual cardiac MRI planning: a single-center prospective evaluation of reliability and scan times.
2025.05	Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.
2025.01	Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
2025.07	Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea.
2025.02	MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
2025.02	Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study.
2024.10	Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study.
2024.06	Variation in immunoglobulin use and impact on survival in myeloma.
2024.06	Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.
2024.06	Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation.
2024.11	Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study.
2024.07	Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome.
2024.09	Genetic Risk Factors for Bortezomib-induced Neuropathic Pain in an Asian Population: A Genome-wide Association Study in South Korea.
2024.04	Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy.
2024.03	Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
2024.07	Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
2024.10	Risk factors for resistant gram-positive bacteremia in febrile neutropenic patients with cancer.
2024.03	Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
2024.01	Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202).
2024.02	Treatment outcomes and prognostic factors of patients with lymphoblastic lymphoma in East Asia.
2024.04	Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
2024.07	Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis.
2024.05	Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea.
2024.04	Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic Leukemia: a single-center analysis of 67 cases.
2024.01	Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
2024.01	Impact of T-Cell Engagers on COVID-19-Related Mortality in B-Cell Lymphoma Patients Receiving B-Cell Depleting Therapy.
2023.12	Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement.
2023.12	A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
2023.08	Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
2023.10	Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
2023.10	Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
2023.09	A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients.
2023.09	Serum Erythropoietin level in anemia of elderly with unclear etiology.
2023.09	Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm.
2023.10	Empirical vs pre-emptive broad-spectrum antifungal therapy for acute myelogenous leukaemia in the era of antimould prophylaxis.
2023.09	Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
2023.09	Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.
2023.08	Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia.
2023.08	Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
2023.06	Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation.
2023.06	Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
2023.06	Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy.
2023.07	A case of donor cell leukemia driven by a de novo NRAS mutation with complex karyotype.
2023.11	A pilot randomized study for optimal red cell transfusion in acute myeloid leukemia patients with intensive chemotherapy.
2023.05	Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation.
2023.06	Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years' real-world experience in a single institute.
2023.11	Identification of novel Carnobacterium maltaromaticum strains in bone marrow samples of patients with acute myeloid leukemia using a metagenomic binning approach.
2023.04	Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition containing L-aspartic acid in patients with acute lymphoblastic leukemia.
2023.09	Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
2023.06	Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study.
2023.10	Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.
2023.02	ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application.
2023.01	Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
2023.04	Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
2023.01	Telomere integrated scoring system of myelodysplastic syndrome.
2023.03	Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH).
2023.03	Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
2023.01	Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
2023.04	Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
2022.11	A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment.
2022.12	Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis.
2023.04	Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study.
2023.09	Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE.
2022.11	The importance of critically short telomere in myelodysplastic syndrome.
2022.11	A database of 5305 healthy Korean individuals reveals genetic and clinical implications for an East Asian population.
2022.10	Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records.
2022.10	Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.
2022.10	Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial
2022.07	Double-stranded RNA induction asa potential dynamic biomarkerfor DNA-demethylating agents.
2022.08	Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome.
2022.07	Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
2022.08	Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.
2022.07	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
2022.05	Characteristics of Sweet syndrome in patients with or without malignancy.
2022.07	Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
2022.05	IDH1/2 mutations in acute myeloid leukemia.
2022.02	Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients.
2022.07	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
2022.01	Successful treatment of angioinvasive aspergillosis causing diaphragmatic rupture with bowel perforation and cerebral aspergillosis in a patient with FLT3-mutated acute myeloid leukemia: A case report.
2022.07	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
2021.12	Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin.
2022.02	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
2022.01	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
2021.12	Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea.
2021.11	Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis.
2022.02	Significance of analyzing circulating plasma cells in multiple myeloma: differences from measuring minimal residual diseases in bone marrow.
2021.08	Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples.
2021.09	Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms.
2021.09	Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study.
2022.02	Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.
2021.08	Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.
2021.06	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
2022.06	Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
2021.07	Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms.
2021.03	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
2021.09	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea.
2021.06	Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
2021.05	Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma.
2021.04	Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?
2021.07	Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
2021.04	Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.
2021.07	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
2021.05	Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
2021.12	Gaucher disease type 1: Unexpected diagnosis in a 75-year old patient presenting with splenomegaly.
2021.02	Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma.
2021.02	Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
2021.01	Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
2021.08	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
2021.17	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
2021.01	Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
2021.01	A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients.
2021.04	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy.
2021.06	Ultradeep Sequencing Analysis of Paroxysmal Nocturnal Hemoglobinuria Clones Detected by Flow Cytometry: PIG Mutation in Small PNH Clones.
2020.12	Proper Read Filtering Method to Adequately Analyze Whole-Transcriptome Sequencing and RNA Based Immune Repertoire Sequencing Data for Tumor Milieu Research.
2020.12	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
2021.07	Association between body image dissatisfaction and poor quality of life and depression among patients with hematopoietic stem cell transplantation.
2021.02	Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.
2021.01	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
2021.03	Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia.